Puma Biotechnology Reports Fourth Quarter and Full Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Puma Biotech (PBYI) Surges Following Results; Analyst Sees Few Excuses Not to Own
March 1, 2019 10:51 AM ESTPuma Biotech (NASDAQ: PBYI) pushes to highs following earnings after the close. Shares are up 42% on volume that is running 24x the norm.
Citi analyst Yigal Nochomovitz said with the launch back on track, they see few excuses left not to own... More
Puma Biotechnology (PBYI) PT Raised to $37 at RBC Capital
March 1, 2019 6:51 AM ESTRBC Capital analyst Kennen MacKay raised the price target on Puma Biotechnology (NASDAQ: PBYI) to $37.00 (from $29.00) while maintaining a Sector Perform rating following results.
MacKay called results "unexpectedly impressive" with +16% q/q growth versus a tepid +4% in Q3.
"Inventory confounds the... More
Puma Biotech (PBYI) Misses Q4 EPS by 3c
February 28, 2019 4:11 PM ESTPuma Biotech (NASDAQ: PBYI) reported Q4 EPS of ($0.80), $0.03 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $71.1 million versus the consensus estimate of $53.65 million.
For earnings history and earnings-related data on Puma Biotech (PBYI) click here.
... More